[1]
Eleftheriou, P.; Geronikaki, A.; Petrou, A. PTP1B inhibition, A promising approach for the treatment of diabetes type II. Curr. Topics. Med. Chem., 2019, 19(4), 246-263. [PMID: 30714526].
[2]
Saxena, M.; Dubey, R. Target enzyme in Alzheimer’s disease: Acetylcholinesterase inhibitors. Curr. Topics. Med. Chem., 2019, 19(4), 264-275. [PMID: 30706815].
[3]
Rekka, E.A.; Kourounakis, P.N.; Pantelidou, M. Xenobiotic metabolising enzymes: Impact on pathologic conditions, drug interactions and drug design. Curr. Topics. Med. Chem., 2019, 19(4), 276-291. [PMID: 30706817].
[4]
Merlani, M.; Barbakadze, V.; Amiranashvili, L.; Gogilashvili, L.; Poroikov, V.; Petrou, A.; Geronikaki, A.; Ciric, A.; Glamoclija, J.; Sokovic, M. New caffeic acid derivatives as antimicrobial agents: Design, synthesis, evaluation and docking. Curr. Topics. Med. Chem., 2019, 19(4), 292-304. [PMID: 30674263].
Current Topics in Medicinal Chemistry
Title:Trends in Enzyme Inhibition and Activation in Drug Design – Part-I
Volume: 19 Issue: 4
Author(s): Athina Geronikaki
Affiliation:
Export Options
About this article
Cite this article as:
Geronikaki Athina , Trends in Enzyme Inhibition and Activation in Drug Design – Part-I, Current Topics in Medicinal Chemistry 2019; 19 (4) . https://dx.doi.org/10.2174/156802661904190411090238
DOI https://dx.doi.org/10.2174/156802661904190411090238 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
30
1
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Drug Induced QT Interval Prolongation
Current Drug Safety CRF Receptors as a Potential Target in the Development of Novel Pharmacotherapies for Depression
Current Pharmaceutical Design Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer’s Disease: A New Approach to Therapy
CNS & Neurological Disorders - Drug Targets The Neurophysiology of Hydrogen Sulfide
Inflammation & Allergy - Drug Targets (Discontinued) Alzheimer's Disease and the Routine Clinical Use of CSF Biomarkers
CNS & Neurological Disorders - Drug Targets An Assessment of the Effects of Azodicarbonamide-containing Diet on Neurobehaviour, Brain Antioxidant Status and Membrane Lipid Peroxidation Status in Rats
Central Nervous System Agents in Medicinal Chemistry Statin Related Memory Dysfunction in a Nigerian Woman: A Case Report
Current Drug Safety Acknowledgements to Reviewers
CNS & Neurological Disorders - Drug Targets Editorial Thematic Issue: Targeting Synaptic Dysfunction and Neural Connectivity in Neurological and Psychiatric Disorders
Current Pharmaceutical Design The Effect of PAOPA, a Novel Allosteric Modulator of Dopamine D2 Receptors, on Signaling Proteins Following Sub-Chronic Administration in Rats
Current Molecular Pharmacology Nutraceutical Status and Scientific Strategies for Enhancing Production of Omega-3 Fatty Acids from Microalgae and their Role in Healthcare
Current Pharmaceutical Biotechnology The Clinical Spectrum, Diagnosis, Pathogenesis and Treatment of Hashimotos Encephalopathy (Recurrent Acute Disseminated Encephalomyelitis)
Current Medicinal Chemistry Brain MRI, Apoliprotein E Genotype, and Plasma Homocysteine in American Indian Alzheimer Disease Patients and Indian Controls
Current Alzheimer Research Manipulation of Microglial Activation as a Therapeutic Strategy in Alzheimers Disease
Current Medicinal Chemistry Inhibition of Butyrylcholinesterase with Fluorobenzylcymserine, An Experimental Alzheimer's Drug Candidate: Validation of Enzoinformatics Results by Classical and Innovative Enzyme Kinetic Analyses
CNS & Neurological Disorders - Drug Targets MicroRNA-Targeted Signaling Pathways in the Autism Spectrum Disorder: Implications for Early Detection and Targeted Therapy
CNS & Neurological Disorders - Drug Targets Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker
Current Pharmaceutical Design Adverse Effects Cause Varenicline Discontinuation: A Meta-Analysis
Current Drug Safety Neuropathic Pain: Some Clues for Future Drug Treatments
Mini-Reviews in Medicinal Chemistry Effect of Handgrip Exercise on QTc Interval During Different Phases of Menstrual Cycle
Vascular Disease Prevention (Discontinued)